Table 2.

Comparison of mean COXEN GEM chemotherapy sensitivity scores for individual drugs and for their combination between patients with pCR and residual cancer

PredictorDrugpCR group GEM Scores (mean ± 95% CI)Residual Cancer GEM Score (mean ± 95% CI)P
In vitro COXEN GEMPaclitaxel0.531 ± 0.2250.289 ± 0.0790.045
5-FU0.447 ± 0.2290.426 ± 0.0740.848
Doxorubicin0.168 ± 0.1700.235 ± 0.0780.459
Cyclophosphamide0.146 ± 0.1760.160 ± 0.0610.879
TFAC0.659 ± 0.1920.601 ± 0.0750.562
In vivo COXEN GEMPaclitaxel0.449 ± 0.1720.221 ± 0.0480.015
5-FU0.262 ± 0.0570.254 ± 0.0230.787
Doxorubicin0.365 ± 0.0980.239 ± 0.0370.019
Cyclophosphamide0.366 ± 0.1350.251 ± 0.0490.106
TFAC0.755 ± 0.1330.595 ± 0.0520.028

NOTE: TFAC, the sum of individual paclitaxel, 5-FU, doxorubicin, and cyclophosphamide scores. Significant results are highlighted in bold.